Inspira Targets U.S. Market Expansion with ART100 Showcase at AmSECT 2026
Event summary
- Inspira will showcase its FDA-cleared ART100 system at the AmSECT 2026 conference via U.S. distributor Glo-Med Networks.
- The ART100 received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures.
- The event targets perfusionists and cardiac surgical teams who influence hospital purchasing decisions.
- Inspira aims to leverage the conference to expand clinical partnerships and distribution footprint in the U.S.
The big picture
Inspira's strategic showcase at AmSECT 2026 underscores its push to capitalize on FDA clearance and expand its U.S. market presence. The move aligns with broader trends in medical technology where regulatory approvals are increasingly becoming a key differentiator in competitive landscapes. The company's focus on engaging clinical decision-makers directly highlights its shift from development to sales execution, a critical phase for commercial-stage medical device companies.
What we're watching
- Market Adoption
- How Inspira's FDA-cleared ART100 will gain traction among U.S. hospitals and cardiac surgical teams.
- Commercial Execution
- Whether Inspira can sustain its commercial pipeline momentum post-conference.
- Competitive Positioning
- The pace at which Inspira can differentiate ART100 in a competitive extracorporeal circulation market.
Related topics